JP2017535611A - トコトリエノールを効果的に送達するための製剤 - Google Patents
トコトリエノールを効果的に送達するための製剤 Download PDFInfo
- Publication number
- JP2017535611A JP2017535611A JP2017545845A JP2017545845A JP2017535611A JP 2017535611 A JP2017535611 A JP 2017535611A JP 2017545845 A JP2017545845 A JP 2017545845A JP 2017545845 A JP2017545845 A JP 2017545845A JP 2017535611 A JP2017535611 A JP 2017535611A
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- oil
- weight
- tocotrienol
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 113
- 238000009472 formulation Methods 0.000 title claims abstract description 105
- 229930003802 tocotrienol Natural products 0.000 title claims abstract description 20
- 239000011731 tocotrienol Substances 0.000 title claims abstract description 20
- 235000019148 tocotrienols Nutrition 0.000 title claims abstract description 20
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 238000012377 drug delivery Methods 0.000 claims abstract description 7
- 239000003921 oil Substances 0.000 claims description 45
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims description 28
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 claims description 23
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 claims description 23
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 22
- 239000000194 fatty acid Substances 0.000 claims description 22
- 229930195729 fatty acid Natural products 0.000 claims description 22
- -1 polyoxy Polymers 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000010521 absorption reaction Methods 0.000 claims description 10
- 150000004665 fatty acids Chemical class 0.000 claims description 10
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 239000007903 gelatin capsule Substances 0.000 claims description 7
- 239000002736 nonionic surfactant Substances 0.000 claims description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims description 5
- 229930182490 saponin Natural products 0.000 claims description 5
- 150000007949 saponins Chemical class 0.000 claims description 5
- 235000017709 saponins Nutrition 0.000 claims description 5
- 229940117972 triolein Drugs 0.000 claims description 5
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 125000005456 glyceride group Chemical group 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 235000021313 oleic acid Nutrition 0.000 claims description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 241000238367 Mya arenaria Species 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 58
- 235000019198 oils Nutrition 0.000 description 34
- 229930003427 Vitamin E Natural products 0.000 description 27
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 27
- 235000019165 vitamin E Nutrition 0.000 description 27
- 239000011709 vitamin E Substances 0.000 description 27
- 229940046009 vitamin E Drugs 0.000 description 27
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 10
- 239000003925 fat Substances 0.000 description 9
- 150000003612 tocotrienol derivatives Chemical class 0.000 description 8
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 150000003712 vitamin E derivatives Chemical class 0.000 description 6
- 229940087168 alpha tocopherol Drugs 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 229960000984 tocofersolan Drugs 0.000 description 5
- 229930003799 tocopherol Natural products 0.000 description 5
- 239000011732 tocopherol Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000002076 α-tocopherol Substances 0.000 description 5
- 235000004835 α-tocopherol Nutrition 0.000 description 5
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Chemical class OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 4
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Chemical class Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 2
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Chemical class OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Chemical class CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Chemical class Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 229940068778 tocotrienols Drugs 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000011722 γ-tocotrienol Chemical class 0.000 description 2
- 235000019150 γ-tocotrienol Nutrition 0.000 description 2
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical class OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 2
- 239000011729 δ-tocotrienol Chemical class 0.000 description 2
- 235000019144 δ-tocotrienol Nutrition 0.000 description 2
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical class OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940064063 alpha tocotrienol Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007886 soft shell capsule Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical class OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 description 1
- 150000003772 α-tocopherols Chemical class 0.000 description 1
- 239000011730 α-tocotrienol Chemical class 0.000 description 1
- 235000019145 α-tocotrienol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Botany (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (25)
- トコトリエノールの改善された送達のための自己乳化薬物送達製剤であって、
トコトリエノール及びその誘導体から選択される脂溶性化合物と、
非イオン界面活性剤からなる群から選択される一つ以上の乳化剤と、
グリセリドからなる群から選択されるオイルキャリアと、を含む前記製剤。 - 前記製剤は、非イオン界面活性剤からなる群から選択される二つの乳化剤を含む、請求項1に記載の製剤。
- 前記乳化剤は、ポリオキシヒマシ油,脂肪酸のポリオキシグリセリド,ポリオキシエチレンソルビタン脂肪酸エステル,ソルビタン脂肪酸エステル,クレモフォール,ショ糖脂肪酸エステル,レシチン,サポニンやこれらの混合物を含む群から選択される、請求項2に記載の製剤。
- 前記乳化剤は、ソルビタン脂肪酸エステル及びポリオキシエチレンソルビタン脂肪酸エステルからなる群から選択される、請求項3に記載の製剤。
- 前記乳化剤は、ソルビタンモノラウレート(スパン20)及びポリオキシエチレンソルビタン20モノオレエート(ポリソルベート80)である、請求項4に記載の製剤。
- 前記乳化剤の少なくとも一つがサポニンである、請求項3に記載の製剤。
- 前記乳化剤の量が前記製剤の約10重量%から約60重量%である、請求項5に記載の製剤。
- 前記乳化剤の量が前記製剤の約15重量%から約45重量%である、請求項7に記載の製剤。
- 前記スパン20と前記ポリソルベート80の重量比率が約1:1から約1:20である、請求項5に記載の製剤。
- 前記スパン20と前記ポリソルベート80の重量比率が約1:2から約1:8である、請求項9に記載の製剤。
- 前記脂溶性化合物がトコトリエノールである、請求項1に記載の製剤。
- 前記脂溶性化合物の量が前記製剤の約5重量%から約60重量%である、請求項11に記載の製剤。
- 前記脂溶性化合物の量が前記製剤の約10重量%から約50重量%である、請求項12に記載の製剤。
- 前記オイルキャリアがグリセロールトリオレアート(GTO)オイルである、請求項1に記載の製剤。
- 前記オイルキャリアの量が前記製剤の約0重量%から約70重量%である、請求項14に記載の製剤。
- 前記オイルキャリアの量が前記製剤の約6重量%から約56重量%である、請求項15に記載の製剤。
- 前記グリセロールトリオレアート(GTO)オイルがトリオレイン(OOO, C18:1)のトリグリセリド(TG)を主に含有する、請求項14に記載の製剤。
- 前記グリセロールトリオレアート(GTO)オイルが前記GTOオイルの約55重量%から約99重量%の量の前記トリオレイン(OOO, C18:1)を含む、請求項17に記載の製剤。
- 前記グリセロールトリオレアート(GTO)オイルが前記GTOオイルの約65重量%から約85重量%の量の前記トリオレイン(OOO, C18:1)を含む、請求項18に記載の製剤。
- 前記製剤は、さらに、オレイン酸,パルミチン酸,ステアリン酸及びこれらの混合物からなる群から選択される脂肪酸を含む、請求項1に記載の製剤。
- 前記製剤は、粉状又はタブレットの形態とされるか、若しくは、ゼラチンカプセルに充填される、請求項1に記載の製剤。
- 前記製剤は、ゼラチンカプセルに充填されており、
前記ゼラチンカプセルは、固いシェルのゼラチンカプセル又は柔らかいシェルのゼラチンカプセルである、請求項21に記載の製剤。 - 前記製剤は、経口で、非経口で、直腸に、又は局所に投与される、請求項1に記載の製剤。
- 前記製剤は、経口での送達のための形状である、請求項23に記載の製剤。
- 脂溶性栄養素の一日所要量の対象者の吸収を補うための、栄養補助製品中の自己乳化製剤の使用であって、
前記自己乳化製剤が、トコトリエノール及びその誘導体から選択される脂溶性化合物と、非イオン界面活性剤からなる群から選択される一つ以上の乳化剤と、グリセリドからなる群から選択されるオイルキャリアと、を含む前記自己乳化製剤の前記使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MYPI2014703502A MY182652A (en) | 2014-11-25 | 2014-11-25 | Formulation for effective tocotrienol delivery |
MYPI2014703502 | 2014-11-25 | ||
PCT/MY2015/050143 WO2016085325A1 (en) | 2014-11-25 | 2015-11-19 | Formulation for effective tocotrienol delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017535611A true JP2017535611A (ja) | 2017-11-30 |
JP6675413B2 JP6675413B2 (ja) | 2020-04-01 |
Family
ID=56074748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017545845A Active JP6675413B2 (ja) | 2014-11-25 | 2015-11-19 | トコトリエノールを効果的に送達するための製剤 |
Country Status (17)
Country | Link |
---|---|
US (2) | US10493055B2 (ja) |
EP (1) | EP3223795B1 (ja) |
JP (1) | JP6675413B2 (ja) |
KR (1) | KR102414627B1 (ja) |
CN (1) | CN106999428B (ja) |
AU (1) | AU2015354848C1 (ja) |
CA (1) | CA2968523C (ja) |
DK (1) | DK3223795T3 (ja) |
ES (1) | ES2898724T3 (ja) |
HU (1) | HUE056584T2 (ja) |
MY (1) | MY182652A (ja) |
NZ (1) | NZ731986A (ja) |
PH (1) | PH12017500943A1 (ja) |
PL (1) | PL3223795T3 (ja) |
PT (1) | PT3223795T (ja) |
SG (1) | SG11201704137RA (ja) |
WO (1) | WO2016085325A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI799599B (zh) * | 2019-06-06 | 2023-04-21 | 華納國際生物科技股份有限公司 | 醫藥或保健品自乳化固體分散組成物 |
WO2023128750A1 (en) | 2021-12-27 | 2023-07-06 | Sime Darby Plantation Intellectual Property Sdn Bhd | Self-emulsifying composition |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7012460A (ja) | 1970-08-22 | 1972-02-24 | ||
CN1045049C (zh) | 1994-10-15 | 1999-09-15 | 吴桂荣 | 一种红花油乳液及其制备方法 |
US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6596306B1 (en) * | 2000-07-07 | 2003-07-22 | David Ho Sue San Ho | Drug delivery system:formulation for fat-soluble drugs |
SG97918A1 (en) * | 2000-06-08 | 2003-08-20 | Hovid Sdn Bhd | A novel drug delivery system: formulation for fat-soluble drugs |
DE10036871A1 (de) * | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe |
JP4316185B2 (ja) | 2002-04-04 | 2009-08-19 | 三菱化学株式会社 | トコフェロール類及びトコトリエノール類の分離方法 |
US20040005339A1 (en) * | 2002-06-28 | 2004-01-08 | Shojaei Amir H. | Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability |
US8489388B2 (en) | 2008-11-10 | 2013-07-16 | Apple Inc. | Data detection |
WO2012033478A1 (en) * | 2010-09-07 | 2012-03-15 | Murty Pharmaceuticals, Inc. | An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
JP2013060551A (ja) | 2011-09-14 | 2013-04-04 | Klueber Lubrication Muenchen Kg | 潤滑グリース組成物 |
CN103827979A (zh) | 2011-09-23 | 2014-05-28 | 纳幕尔杜邦公司 | 包含多元醇酯的介电流体、制备多元醇酯的混合物的方法、以及包含多元醇酯介电流体的电气装置 |
WO2013059729A1 (en) | 2011-10-21 | 2013-04-25 | First Tech International Limited | Tocotrienol compositions |
-
2014
- 2014-11-25 MY MYPI2014703502A patent/MY182652A/en unknown
-
2015
- 2015-11-19 JP JP2017545845A patent/JP6675413B2/ja active Active
- 2015-11-19 CN CN201580063930.4A patent/CN106999428B/zh active Active
- 2015-11-19 PL PL15863611T patent/PL3223795T3/pl unknown
- 2015-11-19 SG SG11201704137RA patent/SG11201704137RA/en unknown
- 2015-11-19 NZ NZ731986A patent/NZ731986A/en unknown
- 2015-11-19 CA CA2968523A patent/CA2968523C/en active Active
- 2015-11-19 WO PCT/MY2015/050143 patent/WO2016085325A1/en active Application Filing
- 2015-11-19 KR KR1020177017273A patent/KR102414627B1/ko active IP Right Grant
- 2015-11-19 HU HUE15863611A patent/HUE056584T2/hu unknown
- 2015-11-19 US US15/529,197 patent/US10493055B2/en active Active
- 2015-11-19 PT PT158636118T patent/PT3223795T/pt unknown
- 2015-11-19 ES ES15863611T patent/ES2898724T3/es active Active
- 2015-11-19 AU AU2015354848A patent/AU2015354848C1/en active Active
- 2015-11-19 EP EP15863611.8A patent/EP3223795B1/en active Active
- 2015-11-19 DK DK15863611.8T patent/DK3223795T3/da active
-
2017
- 2017-05-23 PH PH12017500943A patent/PH12017500943A1/en unknown
-
2018
- 2018-11-30 US US16/205,433 patent/US10478417B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10478417B2 (en) | 2019-11-19 |
JP6675413B2 (ja) | 2020-04-01 |
AU2015354848B2 (en) | 2018-09-13 |
CA2968523C (en) | 2023-10-03 |
CN106999428A (zh) | 2017-08-01 |
US10493055B2 (en) | 2019-12-03 |
AU2015354848A1 (en) | 2017-06-08 |
US20190111021A1 (en) | 2019-04-18 |
CA2968523A1 (en) | 2016-06-02 |
CN106999428B (zh) | 2020-10-20 |
SG11201704137RA (en) | 2017-06-29 |
EP3223795B1 (en) | 2021-09-01 |
ES2898724T3 (es) | 2022-03-08 |
BR112017010912A2 (pt) | 2017-12-26 |
US20170326101A1 (en) | 2017-11-16 |
DK3223795T3 (da) | 2021-11-22 |
NZ731986A (en) | 2018-08-31 |
PL3223795T3 (pl) | 2022-02-14 |
AU2015354848C1 (en) | 2019-07-11 |
EP3223795A1 (en) | 2017-10-04 |
KR20170088936A (ko) | 2017-08-02 |
PT3223795T (pt) | 2021-11-22 |
HUE056584T2 (hu) | 2022-02-28 |
KR102414627B1 (ko) | 2022-06-30 |
WO2016085325A1 (en) | 2016-06-02 |
EP3223795A4 (en) | 2018-07-25 |
MY182652A (en) | 2021-01-27 |
PH12017500943A1 (en) | 2017-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102088978B (zh) | 血脂异常症的改善或治疗药 | |
AU2018100110A4 (en) | Ubiquinone And Ubiquinol Compositions, And Methods Relating Thereto | |
KR101425241B1 (ko) | 리그난류 화합물 함유 o/w/o형 에멀션 및 그것을 함유하는 조성물 | |
JP5096138B2 (ja) | リグナン類化合物含有水中油滴型エマルション及びそれを含有する組成物 | |
JP2009525755A (ja) | 血中脂質健康のための栄養補助食品組成物 | |
US20180243261A1 (en) | Compositions Comprising Urolithin Compounds | |
US10478417B2 (en) | Formulation for effective tocotrienol delivery | |
AU2018100111A4 (en) | Omega-3 Compositions and Methods Relating Thereto | |
Mangrulkar et al. | A comprehensive review on pleiotropic effects and therapeutic potential of soy lecithin | |
WO2024010441A1 (en) | A self-emulsifying drug delivery formulation with improved oral bioavailability of lipophilic compound | |
BR112017010912B1 (pt) | Formulação para a liberação efetiva de tocotrienol | |
US20240156876A1 (en) | Phospholipid compositions for delivery of therapeutic compounds | |
WO2023128750A1 (en) | Self-emulsifying composition | |
JP2006306855A (ja) | 発癌抑制用油脂含有組成物 | |
RU2211043C2 (ru) | Композиция для приготовления лекарственных форм и обогащения продуктов питания, способствующая коррекции нарушений липидного обмена, профилактики и лечения атеросклероза | |
JP2020002057A (ja) | ゲラニルゲラニオールを含有する自己乳化性組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20170602 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180928 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190903 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191105 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200303 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200310 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6675413 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |